The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19

Source: Intensive Care Medicine - Category: Intensive Care Source Type: research

Related Links:

AbstractObjectivesWe investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.Trial designThis is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.ParticipantsInclusion criteria:1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran2. Age ≥18 years (weight ≥35 kg)3. Hospitalized ≤48 hours4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PC...
Source: Trials - Category: Research Source Type: clinical trials
In addition to physical side effects, corticosteroids can affect your mood, thinking, and behavior.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the October 6, 2020 issue
Source: JAMA: This Week's Audio Commentary - Category: General Medicine Authors: Source Type: podcasts
The role of systemic corticosteroids in the treatment of patients with COVID-19. This guideline was triggered on 22 June 2020 by the publication of the preliminary report of the RECOVERY trial, which has now been published as a peer-reviewed paper. Corticosteroids are listed in the World Health Organization (WHO) model list of essential medicines, readily available globally at a low cost, and of considerable interest to all stakeholder groups.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Purpose of review Coronavirus disease 2019 (COVID-19) is a highly contagious and potentially lethal pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No specific antiviral treatment is currently available. The purpose of this review is to highlight the main repurposed drug treatments with in-vitro or in-vivo efficacy against the SARS-CoV-2. Recent findings Recent clinical trials suggested remdesivir, IFN-β-1b and favipiravir have potential clinical and/or virological benefits on patients with COVID-19. Short course of stress dose of corticosteroids might be used as adjunctive tr...
Source: Current Opinion in HIV and AIDS - Category: Infectious Diseases Tags: COVID19: Edited by Zhiwei Chen and Linqui Zhang Source Type: research
Abstract The current COVID-19 pandemic has prompted the urgent requirement for searching effective treatments since the implications are so huge globally as compared to the earlier pandemics. Momentarily, there has been no effective medicine for SARS-CoV-2 infection, and supportive care tends to be the most effective approach to treat COVID-19 patients. The rapidly growing awareness of SARS-CoV-2 virology offers a large number of possible drug targets. The World Health Organisation (WHO) is steadily updating the treatment protocol for COVID-19 based on the recent clinical trials. In the present review, we have sum...
Source: Current Drug Delivery - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Deliv Source Type: research
As of September 26, 2020, the novel coronavirus (SARS-CoV-2) has infected 32 million people worldwide, and killed more than 996,000 persons (Zhou F et al., 2020; http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51). The 2019 COVID pandemic was confirmed to have spread to Europe on January 31, 2020 (Grasselli et al., 2020). Since then, there have been more than 700,000 confirmed cases in Spain, with more than 31,000 deaths. As a result, Spain saw one of the most draconian Covid-19 blockades in Europe, but two months after its lift, the country is on the brink of a second wave of coronavirus infections.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
AbstractThe coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the ...
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
Trump's doctors treated his COVID-19 with corticosteroid drug dexamethasone. That suggests his early response to the coronavirus spurred serious worry.
Source: L.A. Times - Health - Category: Consumer Health News Authors: Source Type: news
With each day since U.S. President Donald Trump reported that he tested positive for COVID-19, his doctors have added a new major therapy to treat the disease, for a total of three at this point. On Friday—the same day that Trump said he tested positive—the President received an experimental combination of two monoclonal antibodies to help his immune system fight the coronavirus infection, according to his physician, Sean Conley. The next day—after he was hospitalized at Walter Reed National Military Medical Center—he received the drug remdesivir, which blocks the coronavirus’s ability to make...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Corticosteroid Therapy | COVID-19 | Intensive Care